Principal Financial Group
ZNTL icon

Principal Financial Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Principal Financial Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,396
Closed -$243K – 2476
2024
Q1 		$243K Buy
15,396
+515
+3% +$7.08K ﹤0.01% 2138
2023
Q4 		$225K Buy
14,881
+241
+2% +$3.52K ﹤0.01% 2134
2023
Q3 		$294K Buy
14,640
+559
+4% +$14.2K ﹤0.01% 2066
2023
Q2 		$397K Buy
14,081
+603
+4% +$14.5K ﹤0.01% 2006
2023
Q1 		$232K Sell
13,478
-922
-6% -$18.7K ﹤0.01% 2148
2022
Q4 		$290K Buy
14,400
+2,509
+21% +$54K ﹤0.01% 2106
2022
Q3 		$257K Buy
11,891
+1,011
+9% +$27.6K ﹤0.01% 2133
2022
Q2 		$306K Sell
10,880
-982
-8% -$26K ﹤0.01% 2172
2022
Q1 		$547K Buy
11,862
+303
+3% +$16.3K ﹤0.01% 2097
2021
Q4 		$972K Sell
11,559
-4,272
-27% -$331K ﹤0.01% 1987
2021
Q3 		$1.05M Buy
15,831
+1,140
+8% +$65.8K ﹤0.01% 1996
2021
Q2 		$782K Buy
14,691
+8,780
+149% +$470K ﹤0.01% 2104
2021
Q1 		$256K Sell
5,911
-1,021
-15% -$44K ﹤0.01% 2320
2020
Q4 		$360K Buy
+6,932
New +$313K ﹤0.01% 2199

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Principal Financial Group's ZNTL Position: Q2 2024 in Review

Principal Financial Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 15,396 shares — an estimated $243K sold.

Principal Financial Group first reported a position in ZNTL in Q4 2020 and held it in 14 quarters. The position peaked at $1.05M in Q3 2021. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • Principal Financial Group reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 15,396 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $243K.
  • Principal Financial Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Principal Financial Group's Zentalis Pharmaceuticals position peaked at $1.05M in Q3 2021.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.